Robert W. Baird analyst Joel Beatty has maintained their bullish stance on ALKS stock, giving a Buy rating on June 4. Joel Beatty has given ...

Robert W. Baird raised the price target for the Alkermes plc (NASDAQ:ALKS) stock to “an Outperform”. The rating was released on March 19, 2024, according to finviz. The research report from JP Morgan ...

Analyst Uy Ear of Mizuho Securities maintained a Buy rating on Alkermes (ALKS – Research Report), retaining the price target of $35.00.

Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect ...

DUBLIN, June 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 ...

Alkermes just unveiled an announcement. Alkermes plc shareholders, during their 2024 Annual Meeting, approved key amendments to the company’s stock plan, including a substantial ...

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Over the past 15 years, on average, racial and ethnic diversity in multiple US regions has increased by 1% to 5%. JAMA study ...

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.

The company has put high expectations on the drug, an orexin-2 antagonist called seltorexant, as a cornerstone of its neuropsychiatry pipeline.

Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th ...

Alkermes ALKS has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings ...